Programme 2018
Thursday, 6 December
* Competing for the MAC Award
09.00-10.35 | CAD 1 | Lecture Hall A |
| Chair: Gert de Borst, Holger Poppert | |
| Barbara Rantner | Clinical variables with an increased late stroke risk |
| David Spence | Spontaneous embolisation on TCD and carotid plaque features |
| Peter Ringleb | Silent infarction and impaired cerebrovascular reactivity |
| Kosmas Paraskevas | Grade of carotid stenosis and stenosis progression |
| Jonathan Nadjiri | MRI features of unstable carotid plaques |
| Jens Göttler | Multi-modal MRI identifies carotid stenosis patients with reduced cerebral blood flow and oxidative metabolism |
| Alison Halliday | Keynote Lecture: CEA or CAS for asymptomatic carotid stenosis – which patients benefit most? |
11.00-12.25 | CAD 2 | Lecture Hall A |
| Chair: Peter Ringleb, Kornelia Kreiser, Michael Kallmayer | |
| Christos Liapis | Total occlusion of the internal carotid artery – not a benign condition |
| Kosmas Paraskevas | Outcomes following eversion vs. conventional CEA in RCTs and observational studies – a systematic review |
| Armelle Meershoek* | Long term outcomes of hybrid revascularization for extracranial symptomatic carotid artery tandem stenosis |
| Klaus Mathias | Early and one year data from the Scaffold (micromesh) CAS Trial |
| Sumaira MacDonald | Control of the microembolic burden of the carotid bifurcation lesion: comparison of various endovascular strategies |
| Ralf Kolvenbach | Transcarotid stenting with flow reversal: does the kind of stent matter? |
| Marc Schermerhorn | Keynote lecture: Transcarotid stenting (T-CAR) vs. CEA and transfemoral CAS in the SVS Vascular Quality Initiative |
12.30-12.50 | Special Lecture 1 | Lecture Hall A |
| Hans Förstl | Cognitive impairment and dementia in politicians |
13.30-14.55 | CAD 3 | Lecture Hall A |
| Chair: Alison Halliday, Claus Zimmer, Leo Bonati | |
| Tilman Reiff | Stroke and TIA rates at one year in SPACE-2: BMT vs. CEA versus CAS in asymptomatic carotid stenosis |
| Richard Bulbulia | Current status and perspectives of ACST-2, CREST-2, and ECST-2 |
| Gert de Borst | Safety of CEA and CAS in patients with a history of coronary heart disease in EVA-3S, SPACE, ICSS, and CREST |
| Christoph Knappich | Local anesthesia reduced the 30-day risk of stroke or death after symptomatic CEA – metaanalysis of five RCTs |
| Dylan Morris* | Risk factors for major operative complications following asymptomatic CEA – 4.440 CEA from VACS, ACAS, ACST-1, and GALA |
| Evelien de Vries* | Carotid stent failure as a predictor for periprocedural stroke or death after CAS – a substudy from ICSS |
| Leo Bonati | Keynote Lecture: Immediate, intermediate, and long-term results after CEA and CAS in four RCTs on symptomatic carotid stenosis |
15.00-15.25 | Special Lecture 2 | Lecture Hall A |
| Christian Baars | Deadly superbugs from Pharma factories – an investigative report from the NDR Hamburg |
17.25-18.30 | CAD 4 | Lecture Hall B or C |
| Chair: Kosmas Paraskevas, Tilman Reiff | |
| Klaus Mathias | Carotid artery aneurysms – what endovascular treatment can achieve |
| Vanessa Pourier | Gadolinium enhancement and white matter lesions in extracranial carotid artery aneurysms |
| Astrid Hoving | The performance of ultrasound particle image velocimetry in a carotid artery phantom with stent |
| Christoph Schäffer | Non-invasive assessment of carotid plaque burden with tomographic ultrasound |
| Armelle Meershoek | Treatment of internal carotid artery NEar occlusiON (NEON study): an individual patient data meta-analysis |
| Ihor Kobza | The choice of the optimal method of surgical correction of atherosclerotic carotid lesions |
| Peter Konstantiniuk | The ASA classification predicts the ipsilateral stroke free survival in asymptomatic octogenarians with elective CEA |
| Evelien de Vries | Standardization of semiautomatic tortuosity measurements in the carotid artery |
| Leonie Fassaert | Defining the awake blood pressure in patients undergoing CEA |
| Pedro Pinto Sousa | Moderate (50%-69%) symptomatic carotis stenosis – what should we do? |
| Michael Kallmayer | Eligibility to RCTs, do RCTs represent the real world? |
* Competing for the MAC Award
09.00-10.40 | AOR 1 | Lecture Hall B or C |
| Chair: Rebecka Hultgren, Benedikt Reutersberg, Jaroslav Pelisek | |
| Ahmed Eleshra | Different zones (0-2) of hybrid de-branching endovascular aortic repair: outcomes and stroke analysis |
| Mikhail Chernyavskiy | Mid-term results of hybrid aortic arch repair |
| Pedro Pinto Sousa | Acute aortic syndrome – three typical case presentations |
| Arnaud Kerzmann | Results of left subclavian artery revascularization prior to elective TEVAR |
| Ahmad Naga | Combined TEVAR and EVAR to treat thoracic Type I B endoleak and infrarenal AAA |
| Rita Augusto | Late Type I A endoleak after EVAS: a unique challenge |
| Albert Busch | Angiogenesis-inhibition and AAA |
| Liu Shengliang | Role of neutrophil extracellular traps in AAA disease development and progression |
| Jasamin Coles-Black | An easily reproducable 3D printed AAA model using open source digital tools |
| Pedro Pinto Sousa | Endovascular aneurysm repair in octogenarians |
| Jacinta Campos | Mycotic aortic aneurysm secondary to intravesical BCG instillation – is an endovascular approach effective? |
| Makhmud Akhmad | Endovascular diagnostics and treatment of acute abdominal bleedings after upper GI surgery |
| Matthias Trenner | Intraarterial CEUS – first experience with a new technique to detect early endoleaks in EVAR |
| Stefan Ockert | Short report: endovascular one stop shopping: EVAR + TAVI |
| Lars Lönn | Computer-controlled aortic occlusion (REBOA) for the treatment of cardiac arrest and bleedings |
| Konstantinos Spanos | Pre- and postoperative factors associated with the persistence of Endoleak Type II after EVAR in the first year of follow up |
| Dittmar Böckler | The impact of low profile devices for TEVAR procedures |
| Piotr Kasprzak | Endograft explantation and aortic reconstruction in a patient with AAA rupture following EVAS (video presentation) |
11.00-12.30 | AOR 2 | Lecture Hall B or C |
| Chair: Lars Maegdefessel, Andrew Baker | |
| Andrew Baker | Exploiting novel targets in vascular remodelling and disease formation |
| Marc Bailey | Vascular smooth muscle cell remodelling potentiates abdominal aortic aneurysm growth |
| Rachael Forsythe | Multi-modality molecular and cellular imaging to predict AAA growth: towards personalised assessment of disease |
| Rebecka Hultgren | Gender aspects in AAA disease |
| Wolf Eilenberg* | The association of neutrophil activation markers with morphological features of AAA |
| Markus Wagenhäuser* | Nicotine is a regulator of segmental aortic stiffening – implications for AAA development |
| Valentina Paloschi* | Aorta-on-a-chip: a novel tool to gain molecular insights into aneurym disease |
13.30-15.00 | AOR 3 | Lecture Hall B or C |
| Chair: Wolfgang Wall, Michael Gee, Markus Kleemann | |
| Thomas Gasser | Predicting three-dimensional AAA growth from CT-A images |
| Stephane Avril | Patient-specific numerical simulation of endovascular aneurysm repair |
| Michael Gee | In Silico EVAR for Abdominal Aortic Aneurysms |
| Tina Cohnert | Advances in biomechanical and structural AAA wall analysis |
| Joy Roy | Biomechanical modeling of AAA growth and rupture – a clinical perspective |
| Benedikt Reutersberg | The SCAN study reveals that cardiovascular patients should be ultrasound-screened for AAA |
* Competing for the MAC Award
15.40-17.05 | PAD 1 | Lecture Hall A |
| Chair: Jonathan Nadjiri, Anders Wanhainen | |
| Jean-Paul de Vries | DETECT-PAD II: computerized and patient specific model to determine pressure gradients in borderline stenosis with MRA/CTA |
| Jos van den Berg | Zero contrast procedure by use of unenhanced MRA and CO2 angiography |
| Michael Rasper | 3D non-contrast-enhanced ECG-gated MR angiography of the lower extremities |
| Jean-Paul de Vries | The REPEAT study: validation of perfusion angiography measurements for below-the-knee arteries in critcal limb ischaemia |
| Marianne Brodmann | Early results from a RCT on below-the-knee drug-eluting balloons |
| Peter Goverde | One year results of real-life use of the latest generation of balloon expandable DES in below-the-knee treatment |
| Achim Neufang | Surgical arterialisation of the plantar venous system for foot salvage after failed endovascular or operative revascularisation |
17.25-18.30 | PAD 2 | Lecture Hall A |
| Chair: Achim Neufang, Alexander Zimmermann | |
| Anders Wanhainen | Open or endovascular revascularization in the treatment of acute lower limb ischaemia |
| Kerstin Stoklasa | Outcomes of a consecutive series of 708 patients with acute limb ischaemia – a single center report from Munich |
| Heli Järve* | Acute mesenteric ischaemia: irreversible vs. reversible bowel damage – a single center experience |
| Shelby Cooper* | Mesenteric vascular injuries in trauma: a National Trauma Data Bank (NTDB) study from the US |
| Adel Hussein Kamhawy | Arterial injury associated with pediatric supracondylar humerus fracture – exploration or observation? |
| Ralf Kolvenbach | Keynote Lecture: Civilian and pediatric vascular trauma management – an overview |
13.30-14.15 | Mini-Symposium 1 | Conference Room 1 |
| Stefan Ockert | The workflow during complex EVAR – mobile vs. fixed C-Arms (with a focus on ARTIS Pheno) |
| Eric Verhoeven | The workflow during FEVAR in the hybrid OR with fusion imaging (syngo EVAR Guidance) |
| Dittmar Böckler | Intraoperative 3D assessment of FEVAR and BEVAR – EVAR guidance and distorsion correction |
15.30-17.00 | SPECIAL SESSION 1 | Lecture Hall B or C |
| Chair: Alexander Oberhuber, Thomas Schmitz-Rixen, Christos Liapis | |
| Tina Cohnert | Advanced radiation protection in the hybrid OR with Zero Gravity |
| Dittmar Böckler | Practical tips in radiation protection for surgical staff in the hybrid OR |
| Heiko Wendorff | Mid-term effects of an Intensive radiation-protectionTraining on the Intraoperative X-ray-radiation exposure in the hybrid OR |
| Stefan Ockert | Radiation exposure during C-arm supported EVAR with the Siemens Pheno system |
| Bijan Modarai | Risks associated with protracted low dose radiation exposure |
| Dittmar Böckler | Evidence of radiation induced cataracts and brain tumors |
| Stefan Ockert | EVAS might be associated with a decrease in intraoperative radiation dose as compared to EVAR |
Friday, 7 December
* Competing for the MAC Award
08.30-10.05 | CAD 5 | Lecture Hall A |
| Chair: Jan Nilsson, Lars Maegdefessel | |
| Martin Dichgans | Stroke Genetics: discovery, biology, and clinical implications |
| Thorsten Kessler | Implementing genetics into clinical practice in cardiovascular disease management |
| Jan Nilsson | Factors associated with progression of carotid disease in high risk patients |
| Judith Sluimer | Interplay of oxygen sensors, inflammation, and cholesterol metabolism in atherosclerosis |
| Pirkka Vikatmaa | Morphology and histology of silent and symptom-causing atherosclerotic carotid plaques – the Helsinki CEA Study 2 |
| Hanna Winter* | Long non-coding RNA NUDT6 regulates fibrous cap thickness in advanced atherosclerosis |
| Joachim Schmidt* | Expression of human somatostatin receptors and glucose transporters in carotid artery stenosis and aneurysms |
10.30-11.40 | CAD 6 | Lecture Hall A |
| Chair: Eva Bartels, Richard Bulbulia | |
| David Spence | Keynote Lecture: Carotid plaque burden predicts future cardiovascular events – why and how I do it! |
| Steven Rogers | Will carotid plaque volume assessed by 3D tomographic ultrasound be an alternative indicator for CEA or CAS? |
| Holger Poppert | How to detect and to stratify DUS findings at the carotid bifurcation (echolucency, ulceration, etc.) |
| Marjolijn Rots* | Correlation between plaque characteristics and presence of preoperative white matter lesions in patients undergoing CEA |
| Igor Koncar | TAXINOMISIS – a multidisciplinary EU project on stratification of patients with carotid artery disease |
* Competing for the MAC Award
08.30-10.05 | AOR 4 | Lecture Hall B |
| Chair: Julian Scott, Matthias Trenner, Eric Verhoeven | |
| Anders Wanhainen | Keynote Lecture: The new ESVS guidelines – what is new and what is different from the 2017 SVS AAA guidelines? |
| Sebastian Debus | Are there any different recommendations in the 2018 AAA guidelines from the German Vascular Society (DGG)? |
| Mike Wyatt | Changes to the management of patients with AAA in the UK: is NICE out of touch with worldwide best practice? |
| Athanasios Giannoukas | Some small AAAs (4.5-5.5 cm) should be treated - how to select them? |
| Thomas Schmitz-Rixen | How valid is the 5/5.5cm diameter threshold for AAA repair and do we need new RCTs to improve the evidence? |
| Jes S Lindholt | Do we need another RCT for AAA 5.0-5.5 or 5.5-6.0 cm? |
| Igor Koncar | Morphological predictors of an increased AAA rupture risk |
| Clark Zeebregts | Accuracy of routine endoscopy diagnosing colonic ischaemia after AAA repair – a meta-analysis |
10.30-12.00 | AOR 5 | Lecture Hall B |
| Chair: Ralf Kolvenbach, Mike Wyatt | |
| Lars Lönn | Qualitative systematic review of studies reporting on re-interventions after elective EVAR |
| Marc Schermerhorn | Selected Type I and III EL at completion of FEVAR are safe to observe |
| Colin Bicknell | Endovascular strategies for treatment of Type I EL in EVAR |
| Albert Busch | Expansion and atrophy – aortic wall development after EVAR with endoleak Type II |
| Jean-Paul de Vries | Determinants of successful and unsuccessful deployment of EndoAnchors in hostile necks – evaluation of >300 implants |
| Athanasios Giannoukas | Expanding the borders in the treatment of pararenal AAAs with Ch-EVAS |
| Clark Zeebregts | The GLOBAL FACT Registry: a world-wide registry with core lab analysis of fenestrated Anaconda for complex aneurysms |
| Alexander Oberhuber | The (JOTEC®) iliAc BRAnch device for exclusion of Hypogastric Artery aneurysMs – ABRAHAM trial |
12:30-12:45 | SPECIAL LECTURE 3 | Lecture Hall A |
| Julian Scott | Sarcopenia and outcomes in vascular surgery |
13.00-14.20 | AOR 6 | Lecture Hall B |
| Chair: Dittmar Böckler, Piotr Kasprzak | |
| Jes S. Lindholt | DANCAVAS trial: the incidence of coexisting aortic aneurysms and do we overdiagnose ascending aortic aneurysms? |
| Martin Czerny | The EACTS/ESVS expert consensus document on thoracic aortic pathologies affecting the aortic arch |
| Ralf Kolvenbach | Status of ascending aortic stent grafts in true aneurysms |
| Martin Czerny | Total endovascular treatment of aortic arch pathologies using branched endografts |
| Celia Riga | Contact force assessment in the arch during TEVAR: how do different graft designs perform? |
| Jonathan Nadjiri | Assessment of flow-displacement and wall-shear-stress by 4D aortic MRA |
| Ali Shahriari | Repair of acute DeBakey I dissections using a novel dissection – specific arch hybrid graft (AMDS) |
14.50-16.40 | AOR 7 | Lecture Hall B |
| Chair: Tina Cohnert, Alexander Zimmermann | |
| Dittmar Böckler | Prevalence of the CTA-based morphological DISSECT predictors in uncomplicated Stanford Type B aortic dissection |
| Igor Koncar | Early TEVAR in acute Type B dissection |
| Bijan Modarai | Contemporary treatment of Type B aortic dissection: is there a need for a disease specific approach to endografting? |
| Eric Verhoeven | Treatment of chronic aortic dissections with fenestrated and branched endografts |
| Celia Riga | Frozen elephant trunk techniques for chronic Type B dissections |
| Athanasios Katsargyris | Inner branches as an additional option besides fenestrations and branches in TAAA branched grafting |
| Colin Bicknell | Prevention and revision of TEVAR utilising EndoAnchors to reduce and treat endoleak |
| Sebastian Debus | The SPIDERgraft: can this novel technique decrease complications after thoracoabdominal repair? |
| Christos Liapis | Side effects of TEVAR and EVAR on the heart – myth or reality? |
| Christian Reeps | Role of abdominal and thoracic aortic surgery in radical cancer resection |
* Competing for the MAC Award
12.45-14.30 | PAD 3 | Lecture Hall A |
| Chair: Marianne Brodmann, Heiko Wendorff, Adel Hussein Kamhawy | |
| Thomas Zeller | Keynote Lecture: Technological advances in the endovascular treatment of calcified peripheral lesions? |
| Peter Goverde | Flow dynamics and patency rates indicate superiority of covered over kissing aortic bifurcation stents |
| Jean-Paul de Vries | 2 year results of the RAPID trial – RCT comparing Legflow DCB with Supera stenting vs. Supera alone for SFA lesions |
| Gunnar Tepe | 2 year results of the COPA CABANA RCT of DCB vs. PTA for femoro-popliteal in-stent restenosis |
| Jos van den Berg | Current status of in-stent restenosis treatment in the SFA |
| Thomas Zeller | EffPac-Trial: Effectiveness of LUMINOR® DCB versus POBA in the SFA |
| Pirkka Vikatmaa | Multimodal revascularization strategies in CLI – the Helsinki approach |
| Martin Lawaetz* | Is stenting of the superficial femoral artery as good as bypass surgery? Data from the Danish Vascular Registry |
| Alexander Zimmermann | The SVS objective performance goals are achievable for surgical therapy in a consecutive CLI all-comers cohort |
| Alexander Gombert* | Closed-incision negative-pressure therapy reduces vascular surgical site infections: the randomized AIMS trial |
| George Geroulakos | Time of complete healing of leg ulcers following revascularization for critical limb ischaemia |
14.50-15.50 | PAD 4 | Lecture Hall A |
| Chair: Christine Espinola-Klein, Jes S. Lindholt | |
| David Spence | Best medical treatment for asymptomatic carotid disease – optimal LDL levels are achievable! |
| Richard Bulbulia | Intensive lipid-lowering for plaque stabilisation and regression? Implications for surgeons and our patients! |
| Barbara Rantner | Cardiovascular morbidity and mortality in patients with intermittent claudication – medical long-term intervention is a MUST |
| Mark Schermerhorn | Survival after lower extremity revascularization for critical limb-threatening ischaemia (CLTI) is better with high-dose statin |
| Thomas Stadlbauer | PCSK9 inhibitor evolocumab in patients with and without PAD – even better than statins? |
15.50-16.40 | PAD 5 | Lecture Hall A |
| Chair: Barbara Rantner, Klaus Mathias | |
| Christine Espinola-Klein | Update on periprocedural and long-term antithrombotic management in PAD |
| Thomas Stadlbauer | Platelet inhibition PLUS low-dose anticoagulation – a new paradigm for all PAD patients? |
| Michael Spannagl | How to assess and individualize platelet inhibition in PAD |
| Marianne Brodmann | Cardiovascular outcomes after lower extremity endovascular or surgical revascularization – the EUCLID trial |
17.00-18.00 | PAD 6 | Lecture Hall A |
| Chair: Christoph Knappich, Christian Reeps, Mohamed Ayman Nagib | |
| Dmitry Dombrovskyi | Transplantation of stem cells of different origin for the treatment of lower limb ischaemia |
| Akshitha Kesharaju | Sarcopenia as predictor of mortality and morbidity following major lower limb amputation |
| Mohamed Ayman Nagib | Transbrachial approach as an alternative method in the management of aortoiliac occlusive arterial diseases |
| Sabine Dallmann-Sieber | Acute occlusions of the infrarenal aorta – single-center experience of 68 patients in a 14-year period |
| Bianca Marinelli Teixeira | Rare atherosclerotic aneurysms of the dorsalis pedis artery in young women – case reports and literature review |
| Sohiel Nagib | Cost-effectiveness of CO2 as contrast medium for the endovascular treatment of PAOD in renal dysfunction |
| Yuriy Levchak | Adventitial cystic disease of the lower extremity main vessels |
12.30-13.30 | Mini-Symposium 2 | Conference Room 1 |
| Tobias Steinke | The endovascular option for AV-fistula creation |
| Tobias Steinke | How to treat AV-fistula stenosis best |
| Houman Jalaie | The right way to treat chronic obstructive venous lesions – tips and tricks in diagnostic, indication, and treatment |
| Houman Jalaie | What did we learn from the "Attract"-Study? |
15.00-16.00 | Mini-Symposium 3 | Conference Room 1 |
| Chair: Ali Shahriari, Martin Czerny |
17.00-18.05 | SPECIAL SESSION 2 | Lecture Hall B |
| Chair: Colin Bicknell, Albert Busch | |
| Mark Kaschwich* | A modular approach for an endovascular training environment using rapid prototyping as part of the Nav-EVAR project |
| Markus Kleemann | Augmented reality for navigated EVAR |
| Lars Lönn | Metric-based virtual reality simulation – a paradigm shift in training for severe stroke |
| Celia Riga | An optimised team training for EVAR & TEVAR – how do you set it up and what is the evidence? |
| Matthias Trenner | The volume-outcome effect in AAA surgery indicates that trained teams perform better in elective and emergency settings |
| Heiko Wendorff | 3D simulation in the Hybrid OR – just a gimmick or a valuable tool? |
Saturday, 8 December
09.00-10.00 | VEN 1 | Lecture Hall B |
| Chair: Claus-Georg Schmedt, Rolf Weidenhagen | |
| Luís Gamas | Venous stenting: initial experience and follow up in a Portuguese center |
| Mohamed Ayman Nagib | Laser crossectomy vs. anterior accessory saphenous vein laser ablation for anterior accessory saphenous vein reflux |
| Sohiel Nagib | Acute upper extremity deep vein thrombosis (DVT) – indications and effectiveness of superior caval filters |
| Mohamed Ismail | Role of inferior vena cava filter insertion prior to thrombolysis of acute iliofemoral deep venous thrombosis |
| Mangesh Tarte | Inferior caval obstruction – limited role of endovenous therapy |
| Andrij Nykonenko | Diagnostic management of the „nutcracker syndrome“ |
| Mangesh Tarte | Combined role of laser ablation, ethanol embolisation, and foam sclerotherapy in the treatment of venous malformations |
| Adel Hussein Kamhawy | Surgical management of high- and low-flow vascular malformations |
10.00-11.05 | VEN 2 | Lecture Hall B |
| Chair: Jan Beyer-Westendorf, Karin Pfister | |
| Armando Mansilha | Treating acute DVT with DOACs – advances and challenges |
| Viktor Pavlychenko | Surgical vs. conservative treatment of deep venous thrombosis: follow-up and quality of life |
| Stefan Ockert | Quality of life and post-thrombotic syndrome after surgical thrombectomy of acute iliofemoral DVT |
| George Geroulakos | Complications of endovascular treatment of May-Thurner syndrome |
| Houman Jalaie | Technical advances in recanalizing chronic venous obstructions – „skipped Y“ and femoral endophlebectomy |
11.30-13.00 | VEN 3 | Lecture Hall B |
| Chair: Armando Mansilha, Houman Jalaie | |
| Reshaabi Srinanthalogen | A novel view at the pathogenesis of varicose veins: proteomic analysis |
| Jan Beyer-Westendorf | SUPRISE – a RCT on thromboembolic complications in superficial-vein thrombosis under Rivaroxaban or Fondaparinux |
| Tobias Hirsch | Interventional treatment of perforator veins |
| Christian Reeps | Is high ligation still an option in superficial-vein thrombosis close to the sapheno-femoral junction? |
| Thomas Pröbstle | Current status of non-termal/non-tumescent saphenous ablation |
| Claus-Georg Schmedt | LEVEL-2 trial – Endovenous Laser Therapy (EVLT) with long wavelength (1940nm) and reduced energy density |
| Tobias Hirsch | What do we know about the allergenic risk of adhesive vein treatments? |
13.30-14.45 | VEN 4 | Lecture Hall B |
| Chair: Thomas Pröbstle, Uta Werthern | |
| Armando Mansilha | Keynote lecture: Why the current international guidelines are not always accurate to define the best technique for varicose veins |
| Mike Wyatt | Multimodal treatment of small saphenous vein reflux |
| Rolf Weidenhagen | Multimodal treatment of greater saphenous vein reflux |
| Karin Pfister | Periprocedural and long-term compression therapy – indications, evidence, and outcomes |
| Houman Jalaie | The postthrombotic syndrome – prevention and recanalizing treatment strategies |